Literature DB >> 19264904

Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment.

Thomas S Wilkinson1, Kevin Dhaliwal, Thomas W Hamilton, Alexander F Lipka, Lesley Farrell, Donald J Davidson, Rodger Duffin, Andrew Conway Morris, Chris Haslett, John R W Govan, Christopher D Gregory, Jean-Michel Sallenave, A John Simpson.   

Abstract

Microaspiration of Pseudomonas aeruginosa contributes to the pathogenesis of nosocomial pneumonia. Trappin-2 is a host defense peptide that assists with the clearance of P. aeruginosa through undefined mechanisms. A model of macrophage interactions with replicating P. aeruginosa (strain PA01) in serum-free conditions was developed, and the influence of subantimicrobial concentrations of trappin-2 was subsequently studied. PA01 that was pre-incubated with trappin-2 (at concentrations that have no direct antimicrobial effects), but not control PA01, was cleared by alveolar and bone marrow-derived macrophages. However, trappin-2-enhanced clearance of PA01 was completely abrogated by CD14- null macrophages. Fluorescence microscopy demonstrated the presence of trappin-2 on the bacterial cell surface of trappin-2-treated PA01. In a murine model of early lung infection, trappin-2-treated PA01 was cleared more efficiently than control PA01 2 hours of intratracheal instillation. Furthermore, trappin-2-treated PA01 up-regulated the murine chemokine CXCL1/KC after 2 hours with a corresponding increase in neutrophil recruitment 1 hour later. These in vivo trappin-2-treated PA01 effects were absent in CD14-deficient mice. Trappin-2 appears to opsonize P. aeruginosa for more efficient, CD14-dependent clearance by macrophages and contributes to the induction of chemokines that promote neutrophil recruitment. Trappin-2 may therefore play an important role in innate recognition and clearance of pathogens during the very earliest stages of pulmonary infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264904      PMCID: PMC2671365          DOI: 10.2353/ajpath.2009.080746

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages.

Authors:  A Ding; N Thieblemont; J Zhu; F Jin; J Zhang; S Wright
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines.

Authors:  J M Sallenave; A Silva; M E Marsden; A P Ryle
Journal:  Am J Respir Cell Mol Biol       Date:  1993-02       Impact factor: 6.914

3.  High incidence of silent aspiration in elderly patients with community-acquired pneumonia.

Authors:  R Kikuchi; N Watabe; T Konno; N Mishina; K Sekizawa; H Sasaki
Journal:  Am J Respir Crit Care Med       Date:  1994-07       Impact factor: 21.405

4.  Two distinct receptors mediate nonopsonic phagocytosis of different strains of Pseudomonas aeruginosa.

Authors:  J P Heale; A J Pollard; R W Stokes; D Simpson; A Tsang; B Massing; D P Speert
Journal:  J Infect Dis       Date:  2001-03-15       Impact factor: 5.226

5.  Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway.

Authors:  Marcus W Butler; Ian Robertson; Catherine M Greene; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  J Biol Chem       Date:  2006-09-15       Impact factor: 5.157

6.  The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation.

Authors:  C Feldman; M Kassel; J Cantrell; S Kaka; R Morar; A Goolam Mahomed; J I Philips
Journal:  Eur Respir J       Date:  1999-03       Impact factor: 16.671

7.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

Review 8.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

9.  Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved.

Authors:  Nicolas W J Schröder; Siegfried Morath; Christian Alexander; Lutz Hamann; Thomas Hartung; Ulrich Zähringer; Ulf B Göbel; Joerg R Weber; Ralf R Schumann
Journal:  J Biol Chem       Date:  2003-02-19       Impact factor: 5.157

10.  Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia.

Authors:  J Rello; V Ausina; M Ricart; J Castella; G Prats
Journal:  Chest       Date:  1993-10       Impact factor: 9.410

View more
  11 in total

1.  Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance.

Authors:  Jessica M Breslow; Joseph J Meissler; Rebecca R Hartzell; Phillip B Spence; Allan Truant; John Gaughan; Toby K Eisenstein
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

2.  Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Sumiti Jain; T Blake Ball; Francis A Plummer; Charles Wachihi; Joshua Kimani; Kenneth L Rosenthal
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  Bone marrow mesenchymal stem cells ameliorate lung injury through anti-inflammatory and antibacterial effect in COPD mice.

Authors:  Hong-Mei Liu; Yi-Tong Liu; Jing Zhang; Li-Jun Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

4.  The compromise of macrophage functions by hyperoxia is attenuated by ethacrynic acid via inhibition of NF-κB-mediated release of high-mobility group box-1.

Authors:  Mao Wang; Samir Gorasiya; Daniel J Antoine; Ravikumar A Sitapara; Wenjun Wu; Lokesh Sharma; Huan Yang; Charles R Ashby; Divya Vasudevan; Michelle Zur; Douglas D Thomas; Lin L Mantell
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

5.  Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.

Authors:  Nicholas A Eisele; Deborah M Anderson
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

6.  CD14 mediates Toll-like receptor 4 (TLR4) endocytosis and spleen tyrosine kinase (Syk) and interferon regulatory transcription factor 3 (IRF3) activation in epithelial cells and impairs neutrophil infiltration and Pseudomonas aeruginosa killing in vivo.

Authors:  Sanhita Roy; Mausita Karmakar; Eric Pearlman
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

7.  Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury.

Authors:  Kevin Dhaliwal; Emma Scholefield; David Ferenbach; Michael Gibbons; Rodger Duffin; David A Dorward; Andrew Conway Morris; Duncan Humphries; Alison MacKinnon; Tom S Wilkinson; William A H Wallace; Nico van Rooijen; Matthias Mack; Adriano G Rossi; Donald J Davidson; Nik Hirani; Jeremy Hughes; Chris Haslett; A John Simpson
Journal:  Am J Respir Crit Care Med       Date:  2012-07-19       Impact factor: 21.405

8.  Trappin-2/elafin modulate innate immune responses of human endometrial epithelial cells to PolyI:C.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Jean-Michel Sallenave; Kenneth L Rosenthal
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

9.  Developing a gene expression model for predicting ventilator-associated pneumonia in trauma patients: a pilot study.

Authors:  Joseph M Swanson; G Christopher Wood; Lijing Xu; Lisa E Tang; Bernd Meibohm; Ramin Homayouni; Martin A Croce; Timothy C Fabian
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

10.  Anti-HIV-1 activity of elafin depends on its nuclear localization and altered innate immune activation in female genital epithelial cells.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; T Blake Ball; Francis A Plummer; Charles Wachihi; Joshua Kimani; Kenneth L Rosenthal
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.